Compare CSPI & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSPI | COYA |
|---|---|---|
| Founded | 1968 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.1M | 126.6M |
| IPO Year | 1994 | 2022 |
| Metric | CSPI | COYA |
|---|---|---|
| Price | $8.93 | $4.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $15.80 |
| AVG Volume (30 Days) | 20.5K | ★ 99.5K |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | ★ 75.00 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $58,730,000.00 | $7,945,753.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,385.72 |
| P/E Ratio | $893.00 | ★ N/A |
| Revenue Growth | 6.36 | ★ 123.57 |
| 52 Week Low | $8.04 | $3.94 |
| 52 Week High | $17.94 | $7.75 |
| Indicator | CSPI | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 41.10 | 39.80 |
| Support Level | $8.04 | $3.94 |
| Resistance Level | $12.78 | $5.16 |
| Average True Range (ATR) | 0.42 | 0.26 |
| MACD | 0.10 | -0.04 |
| Stochastic Oscillator | 58.70 | 13.70 |
CSP Inc develops and markets IT integration solutions, security products, managed IT services, cloud services, purpose-built network adapters, and high-performance cluster computer systems. The firm operates in two segments, namely Technology Solutions, where the company focuses on value-added reseller integrated solutions, including third-party hardware, software, and technical computer-related consulting, and High-Performance Products segments, where the company designs, manufactures, and delivers products and services to customers that require specialized cybersecurity services, networking, and signal processing. It generates a majority of its revenue from the Technology Solutions segment. Geographically, the company generates the majority of its revenue from the Americas.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.